Natco Pharma Board Approves Q2 Results, Declares Interim Dividend, and Progresses Demerger
Natco Pharma announced Q2/H1 FY26 results, declared ₹1.50 interim dividend with November 20 record date, and approved subsidiary incorporation for Crop Health Sciences demerger.
The declaration of an interim dividend is a positive for shareholders. The demerger of the Crop Health Sciences Division is a significant strategic corporate action that could have a medium to long-term impact on the company's structure and valuation. The financial results are also a key update.
The announcement includes a mixed financial performance with a dip in consolidated profit compared to the prior year's corresponding quarter, balanced by a declared interim dividend and a strategic demerger move that could unlock value.
* The Board of Directors of Natco Pharma Limited, in a meeting held on November 14, 2025, approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. * For the quarter ended September 30, 2025, the company reported consolidated revenue from operations of ₹1,363 crore (₹13,630 million) and a consolidated profit for the period of ₹517.9 crore (₹5,179 million). Basic Earnings Per Share (EPS) stood at ₹28.94. * For the half year ended September 30, 2025, consolidated revenue from operations was ₹2,691.9 crore (₹26,919 million) and consolidated profit for the period was ₹998.2 crore (₹9,982 million). Basic EPS for the half year was ₹55.78. * The Board declared a second interim dividend of ₹1.50 (Rupees one and fifty paise only) per equity share of ₹2 each (75%) for the financial year 2025-26. The record date for determining eligible shareholders for this dividend is fixed as Thursday, November 20, 2025. The payment of this interim dividend will commence from November 28, 2025. * Following an earlier intimation dated September 25, 2025, regarding the proposed demerger of the Crop Health Sciences Division, the Board has approved the incorporation of a wholly-owned Subsidiary Company in India. This subsidiary will serve as the Resulting Company for the demerger. * Additionally, the company noted the completion of the acquisition of 35.75% shares of Adcock Ingram Holdings Limited, South Africa, on November 11, 2025, for a total purchase consideration of ZAR 3,873 million (approximately ₹1,875 crore or USD 225 million).
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.